Comparative Pharmacology
Head-to-head clinical analysis: ERYC versus ERYGEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYC versus ERYGEL.
ERYC vs ERYGEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step.
Erythromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking the translocation of peptidyl-tRNA.
250-500 mg orally every 6 hours or 333-500 mg orally every 8 hours; maximum 4 g/day.
Apply a thin layer to affected areas twice daily. Topical use only.
None Documented
None Documented
2–4 hours in adults with normal renal function; prolonged to 4–8 hours in severe hepatic impairment; does not significantly change in renal failure.
Terminal elimination half-life is approximately 1.6 hours (range 1.0–2.5 hours) after topical application, too short to accumulate with daily use.
Primarily biliary excretion of unchanged drug (60–80%); renal excretion accounts for 10–15% of an oral dose, with minimal fecal elimination (<5%).
Primarily hepatic metabolism; less than 10% excreted renally as unchanged drug. Biliary excretion is minimal.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic